PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsFluocinonide
Fluocinonide
Fluocinonide, Vanos (fluocinonide) is a small molecule pharmaceutical. Fluocinonide was first approved as Lidex on 1982-01-01. It is used to treat facial dermatoses, foot dermatoses, hand dermatoses, inflammation, and leg dermatoses amongst others in the USA. The pharmaceutical is active against glucocorticoid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Fluocinonide, Fluocinonide emulsified base, Vanos (discontinued: Fluocinonide, Lidex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fluocinonide
Tradename
Company
Number
Date
Products
VANOSBausch Health CompaniesN-021758 RX2005-02-11
1 products, RLD, RS
Show 6 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
fluocinol pakunapproved drug other2023-01-11
fluocinonideANDA2024-12-19
fluocinonide 0.05% / hyaluronic acid sodium salt 0.5% / niacinamide 4%unapproved drug other2019-05-22
fluocinonide creamANDA2024-05-01
fluoparunapproved drug other2024-12-13
fluovix plusANDA2021-01-13
vanosNew Drug Application2024-02-27
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
pruritusHP_0000989D011537L29
inflammationMP_0001845D007249—
facial dermatoses—D005148—
foot dermatoses—D005533—
hand dermatoses—D006229—
scalp dermatoses—D012536—
leg dermatoses—D007868—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05A: Agents for treatment of hemorrhoids and anal fissures for topical use
— C05AA: Corticosteroids, topical for treatment of hemorrhoids and anal fissures
— C05AA11: Fluocinonide
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AC: Corticosteroids, potent (group iii)
— D07AC08: Fluocinonide
— D07C: Corticosteroids, combinations with antibiotics
— D07CC: Corticosteroids, potent, combinations with antibiotics
— D07CC05: Fluocinonide and antibiotics
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atopic dermatitisD003876EFO_0000274L20—2—2—4
EczemaD004485HP_0000964L30.9—2—2—4
DermatitisD003872HP_0011123L30.9—2—2—4
Alopecia areataD000506EFO_0004192L63———1—1
AlopeciaD000505HP_0002293L64———1—1
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hand-foot syndromeD060831EFO_1001893——1———1
ExanthemaD005076HP_0000988——1———1
Breast neoplasmsD001943EFO_0003869C50—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L401———12
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MycosesD009181—B35-B49————11
LymphomaD008223—C85.9————11
T-cell lymphomaD016399——————11
T-cell lymphoma peripheralD016411——————11
Mycosis fungoidesD009182—C84.0————11
T-cell lymphoma cutaneousD016410——————11
Cutaneous lupus erythematosusD008178EFO_0003834L93.1————11
Localized sclerodermaD012594EFO_1001361L94.0————11
Oral lichen planusD017676——————11
Lichen planusD008010—L43————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFluocinonide
INNfluocinonide
Description
Fluocinonide is an organic molecular entity.
Classification
Small molecule
Drug classtopical steroids (acetal derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Identifiers
PDB—
CAS-ID356-12-7
RxCUI—
ChEMBL IDCHEMBL1501
ChEBI ID—
PubChem CID9642
DrugBankDB01047
UNII ID2W4A77YPAN (ChemIDplus, GSRS)
Target
Agency Approved
NR3C1
NR3C1
Organism
Homo sapiens
Gene name
NR3C1
Gene synonyms
GRL
NCBI Gene ID
2908
Protein name
glucocorticoid receptor
Protein synonyms
Nuclear receptor subfamily 3 group C member 1, nuclear receptor subfamily 3 group C member 1 variant hGR-B(54), nuclear receptor subfamily 3 group C member 1 variant hGR-B(77), nuclear receptor subfamily 3 group C member 1 variant hGR-B(93), nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
Uniprot ID
Q6N0A4
Mouse ortholog
Nr3c1 (14815)
glucocorticoid receptor (Q61629)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Fluocinonide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 861 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,087 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use